Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is -39.74% lower on its value in year-to-date trading and has touched a low of $17.05 and a high of $39.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARWR stock was last observed hovering at around $17.70 in the last trading session, with the day’s gains setting it 0.74%.
Currently trading at $18.44, the stock is -4.85% and -15.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.97 million and changing 4.18% at the moment leaves the stock -30.68% off its SMA200. ARWR registered -30.31% loss for a year compared to 6-month loss of -25.34%. The firm has a 50-day simple moving average (SMA 50) of $21.859 and a 200-day simple moving average (SMA200) of $26.601875.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.87% gain in the last 1 month and extending the period to 3 months gives it a -36.11%, and is -2.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.41% over the week and 4.74% over the month.
Arrowhead Pharmaceuticals Inc. (ARWR) has around 525 employees, a market worth around $2.29B and $19.65M in sales. Profit margin for the company is -2741.43%. Distance from 52-week low is 8.15% and -53.70% from its 52-week high. The company has generated returns on investments over the last 12 months (-69.18%).
with sales reaching $63.82M over the same period.The EPS is expected to shrink by -137.89% this year, but quarterly earnings will post -68.90% year-over-year. Quarterly sales are estimated to grow 296.50% in year-over-year returns.
Arrowhead Pharmaceuticals Inc. (ARWR) Top Institutional Holders
367.0 institutions hold shares in Arrowhead Pharmaceuticals Inc. (ARWR), with institutional investors hold 84.03% of the company’s shares. The shares outstanding are 124.31M, and float is at 118.50M with Short Float at 7.52%. Institutions hold 80.27% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.68 million shares valued at $407.61 million. The investor’s holdings represent 12.7211% of the ARWR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.21 million shares valued at $317.44 million to account for 9.9072 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 8.89 million shares representing 7.21% and valued at over $231.02 million, while FMR LLC holds 5.5256 of the shares totaling 6.81 million with a market value of $177.05 million.
Arrowhead Pharmaceuticals Inc. (ARWR) Insider Activity
The most recent transaction is an insider sale by Oliver Tracie, the company’s Chief Commercial Officer. SEC filings show that Oliver Tracie sold 9,394 shares of the company’s common stock on Jul 02 ’24 at a price of $25.28 per share for a total of $0.24 million. Following the sale, the insider now owns 0.13 million shares.
Arrowhead Pharmaceuticals Inc. disclosed in a document filed with the SEC on May 02 ’24 that Vakiener Victoria (Director) sold a total of 1,799 shares of the company’s common stock. The trade occurred on May 02 ’24 and was made at $23.31 per share for $41935.0. Following the transaction, the insider now directly holds 30205.0 shares of the ARWR stock.
Still, SEC filings show that on Apr 01 ’24, Hamilton James C (Chief Discovery/Trans Medicine) disposed off 6,000 shares at an average price of $28.03 for $0.17 million. The insider now directly holds 204,851 shares of Arrowhead Pharmaceuticals Inc. (ARWR).
